Whom to Start Treatment in Autoimmune Hepatitis
All patients with confirmed autoimmune hepatitis (AIH) should receive immunosuppressive treatment unless they have inactive "burnt-out" cirrhosis without biochemical activity, as untreated AIH leads to progressive fibrosis, cirrhosis, and death. 1
Indications for Treatment Initiation
Standard Indications (Treat Immediately)
- Active disease with elevated transaminases and IgG - This represents the typical presentation requiring prompt immunosuppression 1
- Any degree of interface hepatitis on biopsy - Histological activity warrants treatment regardless of symptom severity 1
- Asymptomatic patients with biochemical abnormalities - Even mild, asymptomatic disease requires treatment because spontaneous resolution is uncertain and 10-year survival without treatment is significantly reduced 2
Special Populations Requiring Treatment
Acute Severe AIH (INR ≥1.5 without cirrhosis or encephalopathy):
- Start high-dose corticosteroids immediately (predniso(lo)ne 0.5-1 mg/kg/day, up to 2 mg/kg in children) 3, 4
- Critical timing factor: Delayed initiation of corticosteroids (>5 days after presentation) independently predicts treatment failure and need for liver transplantation 4
- Baseline INR is the strongest predictor of response - higher INR correlates with worse outcomes 4
- Monitor closely for 1-2 weeks; if no laboratory improvement or clinical worsening occurs, immediately evaluate for liver transplantation 3
AIH with Acute Liver Failure (ALF with hepatic encephalopathy):
- Evaluate directly for liver transplantation rather than prolonged corticosteroid trial 3
- Corticosteroid therapy has not improved overall survival in ALF, and may be deleterious in patients with MELD >40 3
- Hepatic encephalopathy at presentation defines ALF and mandates transplant evaluation over medical management 3
Patients Who Should NOT Receive Treatment
"Burnt-out" cirrhosis without active inflammation:
- Patients with established cirrhosis but normal transaminases, normal IgG, and no histological activity 5
- These patients have low probability of benefit and higher risk of treatment-related complications 5
Decompensated cirrhosis with poor prognostic features:
- Advanced hepatic encephalopathy (grade 3-4) 5
- Severely elevated prognostic scores (MELD >40) 3
- These patients should proceed directly to transplant evaluation rather than immunosuppression 5
Key Clinical Pitfalls
Do not delay treatment waiting for "more severe" disease - Even asymptomatic patients with mild biochemical abnormalities benefit from treatment, as untreated disease progresses unpredictably 2. The 2025 EASL guidelines emphasize that biochemical response within 6 months is associated with significantly lower progression to cirrhosis or need for transplantation 1.
Do not withhold treatment based on:
- Male gender 2
- Absence of conventional autoantibodies 2, 6
- Elderly age (patients ≥60 years actually respond more quickly to treatment) 3
- Pregnancy (well-tolerated with appropriate management, though postpartum exacerbation requires vigilance) 2
Cholestatic features do not exclude AIH - Patients with elevated alkaline phosphatase or GGT may have AIH (possibly overlap syndrome) and still require treatment, though they may show incomplete or delayed response 3. Perform cholangiography to exclude primary sclerosing cholangitis 2.
Treatment Initiation Algorithm
The 2025 EASL guidelines provide the most current first-line approach 1:
Standard first-line therapy:
- Predniso(lo)ne 0.5 mg/kg/day (up to 1 mg/kg/day in severe/advanced disease)
- Plus azathioprine (start 50 mg/day 2 weeks after corticosteroids when bilirubin <6 mg/dL, increase to 1-2 mg/kg/day by week 4)
- Or mycophenolate mofetil (start 1,000 mg/day, increase to 1,500-2,000 mg/day at week 2)
Rapid tapering of corticosteroids is desirable but must follow biochemical response (ALT and IgG normalization) 1. The goal is to minimize corticosteroid exposure while achieving complete biochemical response within 6 months, as this timeline significantly impacts long-term outcomes 3.